Admin Posted May 26, 2019 Share Posted May 26, 2019 Life continues to present challenges, but I feel good about every little task completed. One of these little tasks was completed yesterday when I put in a personal submission to the PBAC about the proposal they are reconsidering about putting apalutamide (Erlyand® in Australia, Erleada® in USA) on the PBS. This is a reminder to other members that Wednesday 12 June 2019 is the closing date for submissions. You may have something useful to offer if: you are currently non-metastatic, castrate resistant; OR you have been non-metastatic, castrate resistant in the past, but missed out on the benefits of Apalutamide (or a similar drug such as abiraterone, Zytiga or enzalutamide, Xtandi) , OR you have been non-metastatic, castrate resistant in the past, but enjoyed the benefits of Apalutamide (or a similar drug such as abiraterone, Zytiga or enzalutamide, Xtandi; OR you may be non-metastatic, castrate resistant in the future. If you do have something to offer, the PBAC wishes to hear from you on this proposal. More details here: Jim Link to comment Share on other sites More sharing options...
Kevin Martin Posted May 27, 2019 Share Posted May 27, 2019 Hello Jim, I just sent a submission about my experience with Enzalutamide. Thanks Link to comment Share on other sites More sharing options...
Admin Posted May 27, 2019 Author Share Posted May 27, 2019 Kevin Thanks for letting me know. It is important that people who make the decisions understand how the people affected by the availability of the drugs really experience them. Jim Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.